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Cerebral small vessel disease and incident
parkinsonism
The RUN DMC study
ABSTRACT
Objective: To investigate the relation between baseline cerebral small vessel disease (SVD) and
the risk of incident parkinsonism using different MRI and diffusion tensor imaging (DTI) measures.
Methods: In the Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort
(RUN DMC) study, a prospective cohort study, 503 elderly participants with SVD and without par-
kinsonism were included in 2006. During follow-up (2011–2012), parkinsonism was diagnosed
according to UK Brain Bank criteria. Cox regression analysis was used to investigate the association
between baseline imaging measures and incident all-cause parkinsonism and vascular parkinsonism
(VP). Tract-based spatial statistics analysis was used to identify differences in baseline DTI meas-
ures of white matter (WM) tracts between participants with VP and without parkinsonism.
Results: Follow-upwas available from501 participants (mean age 65.6 years; mean follow-up duration
5.2 years). Parkinsonism developed in 20 participants; 15 were diagnosed with VP. The 5-year risk of
(any) parkinsonismwas increased for those with a high white matter hyperintensity (WMH) volume (haz-
ard ratio [HR] 1.8 per SD increase, 95% confidence interval [CI] 1.3–2.4) and a high number of lacunes
(HR 1.4 per number increase, 95%CI 1.1–1.8) at baseline. For VP, this risk was also increased by the
presence of microbleeds (HR 5.7, 95% CI 1.9–16.8) and a low gray matter volume (HR 0.4 per SD
increase, 95%CI 0.2–0.8). Lower fractional anisotropy values in bifrontal WM tracts involved in move-
ment control were observed in participants with VP compared to participants without parkinsonism.
Conclusions: SVD at baseline, especially a high WMH volume and a high number of lacunes, is
associated with incident parkinsonism. Our findings favor a role of SVD in the etiology of
parkinsonism. Neurology® 2015;85:1569–1577
GLOSSARY
CI 5 confidence interval; DTI 5 diffusion tensor imaging; FA 5 fractional anisotropy; FLAIR 5 fluid-attenuated inversion
recovery; GM 5 gray matter; HR 5 hazard ratio; IPD 5 idiopathic Parkinson disease; MD 5 mean diffusivity; MMSE 5 Mini-
Mental State Examination; PSP 5 progressive supranuclear palsy; RUN DMC 5 Radboud University Nijmegen Diffusion
Tensor and Magnetic Resonance Cohort; SPM 5 Statistical Parametric Mapping; STRIVE 5 Standards for Reporting Vas-
cular Changes on Neuroimaging; SVD5 small vessel disease; TBSS5 tract-based spatial statistics;UPDRS-m5motor part
of the Unified Parkinson’s Disease Rating Scale; VP 5 vascular parkinsonism; WM 5 white matter; WMH 5 white matter
hyperintensity.
Cerebral small vessel disease (SVD) is a frequent finding on brain imaging of the elderly pop-
ulation1 and has been identified as a cause of motor impairment2 and gait and balance decline
over time.3 SVD has also been related to parkinsonism, with evidence coming from cross-
sectional autopsy studies that found pathologic proof of SVD in patients with parkinsonism,
who did not exhibit evidence of histopathologic findings compatible with parkinsonism, includ-
ing Lewy bodies or tau inclusions.4,5 Whether parkinsonism is a direct consequence of SVD or a
coincidental finding is unknown.
The imaging spectrum of SVD is rapidly expanding from lesions visible on conventional
MRI, including white matter hyperintensities (WMHs), lacunes, microbleeds, and (sub)cortical
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atrophy,6 to changes in diffusion measures of
the white matter (WM) assessed by diffusion
tensor imaging (DTI),7 which is regarded as an
index of WM structural integrity. Recent
cross-sectional DTI studies have shown a rela-
tion between diffusion abnormalities in the
WM and parkinsonism8,9; however, longitudi-
nal studies investigating the role of these MRI
and DTI characteristics in the development of
parkinsonism are currently lacking. We there-
fore prospectively investigated the relation
between SVD, using baseline MRI and DTI
measures, including tract-based spatial statis-
tics (TBSS), and the development of parkin-
sonism, in order to gain insight into the role of
SVD in incident parkinsonism.
METHODS Study population. This study is embedded in
the Radboud University Nijmegen Diffusion Tensor and Mag-
netic Resonance Cohort (RUNDMC) study, a prospective cohort
study that investigates the risk factors and clinical consequences of
functional and structural brain changes as assessed by MRI in 503
independently living elderly participants with SVD. The primary
outcome of the longitudinal part of the RUN DMC study is inci-
dent parkinsonism and dementia. The recruitment, study ratio-
nale, and protocol of the RUN DMC study have been
described in detail elsewhere.10 SVD was defined as the presence
of any WMH or lacunes of presumed vascular origin on brain
imaging,11 because the onset of SVD is often insidious and clin-
ically heterogeneous with acute symptoms (TIAs or lacunar syn-
dromes), or subacute symptoms, including cognitive, motor, or
mood disturbances.12 All consecutive patients referred to our
department who underwent diagnostic brain imaging (CT or
MRI scan) for several reasons (e.g., stroke, TIA, cognitive com-
plaints) were selected for participation. Inclusion criteria were age
between 50 and 85 years and SVD on brain imaging. Main exclu-
sion criteria were parkinsonism, dementia, SVDmimics, andMRI
contraindications. Patients eligible because of a lacunar syndrome
were included .6 months after the event.
Baseline assessment, including an extensive cognitive and
motor evaluation and a cerebral MRI, took place in 2006 among
503 participants. In 2011–2012, this assessment was repeated; 2
participants were lost to follow-up (but not deceased), 49 had
died, and 54 refused an in-person follow-up, but their clinical
endpoints were available; 398 participated in the follow-up exam-
ination (figure e-1 on theNeurology®Web site at Neurology.org).
Standard protocol approvals, registrations, and patient
consents. All participants signed an informed consent form. The
Medical Review Ethics Committee region Arnhem-Nijmegen
approved the study.
Screening for parkinsonism. A flowchart of the parkinsonism
screening is shown in figure 1. The presence of parkinsonian signs
was evaluated during an in-person follow-up assessment (n 5
398) by 2 trained residents in neurology by using the motor
part of the Unified Parkinson’s Disease Rating Scale (UPDRS-m,
27 items, score 0–108).13 Parkinsonism was defined as the presence
of bradykinesia and at least one of the 3 following signs: tremor,
rigidity, or gait and postural instability, according to the UK
Parkinson’s Disease Society Brain Bank criteria.14 We screened
the presence of these 4 signs on the basis of previously established
parkinsonian sign scores derived from the UPDRS-m,15 including
limb bradykinesia (based on 8 items: right and left finger taps,
handgrip, hand pronation-supination, and leg agility), rigidity
(based on 5 items: rigidity of neck and the 4 extremities), tremor
(based on 7 items: rest tremor of lip/chin and 4 extremities and
action tremor of both arms), and parkinsonian gait (based on 5
items: arise from chair, posture, gait, postural stability, and
body bradykinesia). We considered bradykinesia as present
when $1 items on limb bradykinesia had a score of $2,13,16
to guarantee a high sensitivity of this main symptom of parkinsonism.
The other 3 signs (tremor, rigidity, and gait and postural instability)
were considered present when the participant had either $2
items with a score of $1 or 1 item with a score of $2 in that
specific category.
Participants were considered screen-positive when (1) they
were already diagnosed with parkinsonism by a neurologist after
baseline assessment or (2) they had bradykinesia and one or more
of the other 3 signs,17 according to abovementioned criteria, or
(3) had UPDRS-m score $10, but did not meet the criteria
mentioned in (1) or (2). We added this last criterion because
other comorbidities (e.g., stroke, severe polyneuropathy, or rheu-
matic disease) often influence UPDRS-m scores, which could
hinder the evaluation of the presence of parkinsonism.
Of the 398 participants, 68 were considered screen-positive
and 40 of them were subsequently examined by a neurologist spe-
cialized in movement disorders (R.A.J.E.) for the presence of par-
kinsonism (10 were diagnosed with parkinsonism; 30 were not).
The remaining 28 participants refused this additional evaluation,
and for them a consensus diagnosis of parkinsonism was made by
a panel, consisting of 2 neurologists, one of whom was specialized
in movement disorders (R.A.J.E.). They reviewed all available
information on motor performance and imaging, including (1)
UPDRS-m scores at baseline and follow-up assessment; (2) infor-
mation from follow-up neurologic examination, including muscle
strength, gait, upper motor neuron signs, sensory deficits, and
(primitive) reflexes; (3) medical history; (4) medication; (5)
follow-up MRI scan, or if not available, baseline imaging (n 5
12); and (6) if applicable, information on the presence of parkin-
sonism from their treating neurologist. Of these 28 participants, 8
were diagnosed with parkinsonism.
For the participants who did not participate in person (49
deceased and 54 not able to visit our research center), medical re-
cords were reviewed and their treating physician was contacted for
information on the presence of parkinsonism. In 2 participants,
the diagnosis of parkinsonism was reported; after review by the
panel, these diagnoses were confirmed, yielding a total of 20 par-
ticipants with incident parkinsonism.
Parkinsonism was diagnosed based on UK Parkinson’s Dis-
ease Society Brain Bank criteria for idiopathic Parkinson disease
(IPD),14 Zijlmans et al.5 criteria for vascular parkinsonism (VP),
and National Institute of Neurological Disorders and Stroke–
Society for Progressive Supranuclear Palsy criteria for progressive
supranuclear palsy (PSP).14 VP requires the presence of relevant
cerebrovascular disease on neuroimaging, operationalized in our
study as WMHs beginning to become confluent (Fazekas score
$2),18 or the presence of lacunes in basal ganglia or thalamus.5
Participants with drug-induced parkinsonism were excluded (n5
1). The age at onset of parkinsonism was defined as the midpoint
between the date on which parkinsonism was first identified and
baseline RUN DMC assessment,19 or if applicable the date at
which participants were last reviewed by a neurologist without
notification of hypokinetic-rigid symptoms in-between baseline
and follow-up assessment.
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MRI scanning and processing. Baseline MRI was performed
on a single 1.5T Magnetom Sonata scanner (Siemens Medical Sol-
utions, Erlangen, Germany), and included a 3D T1 magnetization-
prepared rapid gradient echo, fluid-attenuated inversion recovery
(FLAIR), gradient-echo T2*-weighted sequence and a DTI
sequence. Details have been described in detail elsewhere.10
WMHs were manually segmented on the FLAIR images, with
a good interrater variability (intraclass correlation coefficient 0.99).
The ratings of lacunes and microbleeds were revised according to
the recently published Standards for Reporting Vascular Changes
on Neuroimaging (STRIVE)6 by trained raters blinded to clinical
information. The intrarater and interrater variability in a random
sample of 10% was good, with weighted kappa of 0.87 and 0.95,
respectively, for presence of lacunes, and 0.85 and 0.86 for presence
of microbleeds. Automated segmentation on T1 images was per-
formed using Statistical Parametric Mapping (SPM5), to obtain
gray matter (GM), WM, and CSF probability maps. These maps
were binarized by applying a 0.5 threshold and summed to supply
total volumes. All volumes were normalized to the total intracranial
volume to adjust for head size.20 The DTI analysis has been
described in detail elsewhere.10 For TBSS analysis, DTIFit within
the FSL toolbox was used to generate fractional anisotropy (FA) and
mean diffusivity (MD) images, which were imported into the TBSS
pipeline.21 To create a FA skeleton, the mean FA image was thinned
and subsequently this skeleton was thresholded at 0.3 to include
major WM tracts. Of the 501 participants (2 were lost to follow-
up), 4 were excluded from TBSS analysis because of imaging arte-
facts, 54 because of territorial infarcts, 2 because of missing values of
microbleeds, and 5 because of parkinsonism other than VP, yield-
ing a subgroup of 436 participants (9 with VP and 427 without
parkinsonism).
Other measurements. We used the Mini-Mental State
Examination (MMSE) score to indicate global cognitive status.
Figure 1 Flowchart of parkinsonism case-finding during follow-up
IPD 5 idiopathic Parkinson disease; OPD 5 outpatient department; PSP 5 progressive supranuclear palsy; SVD 5 cerebral small vessel disease; VP 5
vascular parkinsonism.
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Statistical analysis. Statistical analyses were performed using IBM
(Armonk, NY) SPSS Statistics 20. The person-years at risk for each
participant were defined as the time between baseline assessment
and onset of parkinsonism, date of follow-up assessment, or death,
depending on which event occurred first. Cumulative risk of (any)
parkinsonism and separate for VP, being the largest group in our
study, was estimated with a Kaplan-Meier analysis. Differences in
baseline characteristics between participants with VP or IPD/PSP
and without parkinsonism were tested by univariate analyses, using
an independent samples t test, x2 test, Fisher exact test, or Mann-
Whitney U test, when appropriate (table 1).
Cox regression analysis was used to calculate hazard ratios
(HRs) with their corresponding 95% confidence intervals (CIs)
of baseline imaging characteristics for (any) parkinsonism and
VP separately. Adjustments were made for baseline age, sex,
UPDRS-m score, territorial infarcts, and for GM volume or 4
SVD characteristics (WMH volume, WM volume, number of
lacunes, and microbleeds). Verification of proportionality of haz-
ards was performed by examining Schoenfeld residuals. Bonferro-
ni corrections were used to correct for multiple comparisons;
p values #0.00714 were considered significant.
To compare voxel-wise analyses of DTI measures between
those with VP and without parkinsonism, a 2-sample t test was
performed, using a permutation-based statistical interference as
part of FSL toolbox (randomise), with a standard number of
permutation tests set at 5,000. To identify significant
associations, a threshold-free cluster enhancement with a p value
,0.025, corrected for multiple comparisons, was used.
RESULTS The total study population consisted of
501 participants; 2 were lost to follow-up. Mean
follow-up duration was 5.2 years (SD 0.7).
Parkinsonism developed in 20 participants (4.0%);
15 were diagnosed with VP, with all patients having
predominantly lower body symptoms and a bilateral
onset, 4 with IPD, and 1 with PSP. The cumulative
5-year risk of (any) parkinsonism was 3.5% (95%
CI 1.9–5.2) and of VP 2.9% (95% CI 1.4–4.4).
One participant with VP was excluded because of
baseline T1/T2 artefacts.
Table 1 shows the baseline characteristics of the
total study population, and for participants with VP,
IPD/PSP, and without parkinsonism separately. The
mean baseline age of the total population was 65.6
years (SD 8.8); 56.8% were men. Participants with
VP, in comparison to participants without parkinson-
ism, were older (p 5 0.009), had a lower MMSE
score (p5 0.039), and had a higher UPDRS-m score
(p 5 0.001) at baseline. Furthermore, all baseline
Table 1 Baseline characteristics of the total study population and of participants with VP, with IPD/PSP, and without parkinsonism
Total, n 5 500 VP, n 5 14 IPD/PSP, n 5 5 No parkinsonism, n 5 481
Baseline demographics
Age at baseline, y, mean 6 SD 65.6 6 8.8 70.7 6 6.3 68.7 6 8.1 65.5 6 8.8
Male, n (%) 284 (56.8) 9 (64.3) 4 (80.0) 271 (56.3)
MMSE at baseline, mean 6 SD 28.1 6 1.6 27.4 6 1.4 27.0 6 1.9 28.2 6 1.6
UPDRS-m total score at baseline, median (IQR) 0.0 (0.0; 1.0)a 2.0 (0.0; 6.0) 3.0 (2.0; 4.0)a 0.0 (0.0; 1.0)
Baseline MRI measures
WMH volume, mL, median (IQR) 7.2 (3.6; 18.4) 30.0 (16.6; 56.9) 5.4 (3.7; 22.1) 7.0 (3.4; 17.7)
Lacunes, n (%) 134 (26.8) 11 (78.6) 2 (40.0) 121 (25.2)
Microbleeds, n (%) 80 (16.0)b 8 (57.1) 0 (0.0) 72 (15.0)b
White matter volume, mL, mean 6 SD 464.7 6 51.9 422.9 6 63.4 452.9 6 33.8 466.1 6 51.2
Gray matter volume, mL, mean 6 SD 630.9 6 53.9 580.0 6 48.2 634.5 6 76.7 632.3 6 53.2
Territorial infarcts, n (%) 56 (11.2) 5 (35.7) 1 (20.0) 50 (10.4)
Baseline DTI measures, mean 6 SD n 5 497c n 5 14 n 5 5 n 5 478c
White matter global FA 0.33 6 0.02 0.31 6 0.03 0.34 6 0.02 0.33 6 0.02
WMH global FA 0.34 6 0.03 0.31 6 0.03 0.35 6 0.03 0.34 6 0.03
NAWM global FA 0.33 6 0.02 0.31 6 0.03 0.34 6 0.02 0.33 6 0.02
White matter global MD 0.89 6 0.05 0.95 6 0.05 0.87 6 0.04 0.89 6 0.04
WMH global MD 1.00 6 0.07 1.09 6 0.06 0.99 6 0.07 1.00 6 0.07
NAWM global MD 0.89 6 0.04 0.94 6 0.04 0.87 6 0.03 0.89 6 0.04
Abbreviations: DTI 5 diffusion tensor imaging; FA 5 fractional anisotropy; IPD 5 idiopathic Parkinson disease; IQR 5 interquartile range; MD 5 mean
diffusivity (*1023 mm2/s); MMSE 5 Mini-Mental State Examination; NAWM 5 normal-appearing white matter; PSP 5 progressive supranuclear palsy;
UPDRS-m 5 Unified Parkinson’s Disease Rating Scale motor score; VP 5 vascular parkinsonism; WMH 5 white matter hyperintensities.
Brain volumes are represented normalized to the total intracranial volume.
aOne participant was excluded because of missing values of UPDRS-m at baseline.
b Four participants were excluded because of missing values of microbleeds at baseline.
c Three participants were excluded because of baseline DTI artefacts.
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imaging characteristics shown in table 1 differed sig-
nificantly (p , 0.05) between those groups.
One participant with IPD was excluded because of
a missing baseline UPDRS-m score.
There was a strong relation betweenWMHvolume
and the number of lacunes and the 5-year risk of (any)
parkinsonism (table 2). The 5-year risk of VP was
increased for those with a high WMH volume (HR
2.0 per SD increase [mL]; 95% CI 1.4–2.7), a high
number of lacunes (HR 1.5 per number increase; 95%
CI 1.2–1.9), presence of microbleeds (HR 5.7; 95%
CI 1.9–16.8), and a low GM volume (HR 0.4 per SD
increase [mL]; 95% CI 0.2–0.8) (table 3).
A TBSS analysis showed differences in baseline DTI
values between participants with VP and those without
parkinsonism (figure 2). Lower FA values were seen
in WM tracts in the bilateral frontal and right parietal
lobe—genu of corpus callosum, internal capsule, supe-
rior longitudinal fasciculus, forceps minor, inferior
fronto-occipital fasciculus, cingulum bundle, superior
and posterior (right) corona radiate, and right posterior
thalamic radiation—in participants with VP, even after
adjustment for different SVD characteristics. In addi-
tion, higher MD values were seen in VP patients in a
similar pattern, although most voxels lost signal after
adjustment for SVD, except in the anterior corona
radiata (data not shown).
DISCUSSION This is a unique prospective study
investigating the relation between cerebral SVD at
baseline and the risk of incident parkinsonism. We
showed that a high WMH volume and a high num-
ber of lacunes were associated with an increased
5-year risk of (any) parkinsonism. For VP, this risk
was also increased by the presence of microbleeds
and a low GM volume. Furthermore, we observed
lower FA values especially in bifrontal WM tracts
involved in movement control in participants with
Table 2 Relation between baseline MRI and DTI measures and the risk of (any) parkinsonism at follow-up
Hazard ratio (95% CI),
adjusted for baseline age, sex,
baseline UPDRS-m score, and
territorial infarcts p Value
Hazard ratio (95% CI), in
addition adjusted for gray
matter volumea or SVD
characteristicsb p Value
Baseline MRI measures (n 5 499)c
WMH volume, per SD (mL) 1.74 (1.33–2.27) ,0.001d 1.75 (1.31–2.35)a ,0.001d
Lacunes, presence 4.74 (1.55–14.51) 0.006d 3.66 (1.19–11.32)a 0.024
Lacunes, per number 1.52 (1.21–1.91) ,0.001d 1.43 (1.13–1.80)a 0.003d
Microbleeds, presencee 3.87 (1.50–10.01) 0.005d 3.52 (1.36–9.09)a 0.009
Microbleeds, per numbere 1.07 (0.98–1.17) 0.144 1.09 (0.99–1.19)a 0.087
White matter volume, per SD (mL) 0.73 (0.41–1.28) 0.267 0.64 (0.34–1.18)a 0.151
Gray matter volume, per SD (mL) 0.42 (0.23–0.76) 0.004d 0.48 (0.27–0.87)b 0.016
Hazard ratio (95% CI),
adjusted for baseline age, sex,
baseline UPDRS-m score, and
territorial infarcts p Value
Hazard ratio (95% CI), in
addition adjusted for gray
matter volumea and SVD
characteristicsb p Value
Baseline DTI measures, (n 5 496)f
White matter global FA, per SD 0.76 (0.47–1.24) 0.275 1.40 (0.80–2.44)a,b 0.244
WMH global FA, per SD 0.54 (0.30–0.97) 0.038 0.90 (0.49–1.66)a,b 0.729
NAWM global FA, per SD 0.77 (0.47–1.26) 0.300 1.42 (0.81–2.49)a,b 0.225
White matter global MD, per SD 1.70 (0.99–2.90) 0.053 0.71 (0.36–1.42)a,b 0.333
WMH global MD, per SD 2.49 (1.45–4.28) 0.001d 1.39 (0.4–3.01)a,b 0.401
NAWM global MD, per SD 1.48 (0.85–2.58) 0.165 0.66 (0.35–1.27)a,b 0.218
Abbreviations: CI 5 confidence interval; DTI 5 diffusion tensor imaging; FA 5 fractional anisotropy; MD 5 mean diffusivity
(*1024 mm2/s); NAWM 5 normal-appearing white matter; per SD 5 hazard ratios per SD difference from the mean; SVD 5
small vessel disease; UPDRS-m 5 Unified Parkinson’s Disease Rating Scale motor score; WMH 5 white matter
hyperintensities.
a In addition adjusted for gray matter volume.
b In addition adjusted for SVD characteristics: including white matter volume, WMH volume, number of lacunes and
microbleeds.
cOne participant with idiopathic Parkinson disease was excluded in addition because baseline UPDRS-m score was
missing.
dSignificant after Bonferroni correction.
e Four participants were excluded because of missing values of microbleeds at baseline.
f Three participants were excluded in addition because of baseline DTI artefacts.
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VP compared to participants without parkinsonism,
independent of SVD.
Major strengths of our study are its longitudinal
and single-center design, which allowed us to use
identical motor and cognitive assessments during
baseline and follow-up. Furthermore, the large sam-
ple size and high follow-up rate of 99.6% are main
advantages. Moreover, all imaging data were analyzed
by raters blinded to clinical information with a good
intrarater and interrater variability. Finally, we were
able to make appropriate adjustments, reducing the
risk of confounding. We intentionally did not adjust
for vascular risk factors as we considered them part of
the causal chain between SVD and parkinsonism.
Several methodologic issues need to be addressed.
First, because of the small number of patients with par-
kinsonism in our study, our results should be inter-
preted with caution. Second, we were not able to
diagnose parkinsonism in the same way for all patients.
For participants who were not able to participate in
person, we had to rely on information from medical
files and we could have missed the diagnosis of parkin-
sonism in some, since parkinsonism is frequently
accepted as part of normal aging. Some participants
who participated in person and were considered
screen-positive for the presence of parkinsonian signs
refused additional evaluation by a neurologist special-
ized in movement disorders (28 of 68 participants).
However, all 28 participants were examined in the
follow-up assessment by 2 skilled neurologists in train-
ing with extensive experience in diagnosing parkinson-
ism, after which a consensus diagnosis was made by an
expert panel. The similarity of the diagnostic
approaches is well-illustrated by a virtual identical pro-
portion of the patients with parkinsonism identified by
the 2 approaches. Third, misclassification could have
occurred as the accuracy of clinical diagnosis of the dif-
ferent etiologies underlying parkinsonism, compared
to neuropathologic diagnosis, is relatively low.22 We
therefore initially classified any parkinsonism;
Table 3 Relation between baseline MRI and DTI measures and the risk of vascular parkinsonism at follow-up
Hazard ratio (95% CI),
adjusted for baseline age, sex,
baseline UPDRS-m score, and
territorial infarcts p Value
Hazard ratio (95% CI), in
addition adjusted for gray
matter volumea or SVD
characteristicsb p Value
Baseline MRI measures (n 5 495)c
WMH volume, per SD (mL) 1.92 (1.45–2.55) ,0.001d 1.99 (1.44–2.73)a ,0.001d
Lacunes, presence 6.60 (1.68–25.89) 0.007d 4.68 (1.18–18.56)a 0.028
Lacunes, per number 1.61 (1.26–2.05) ,0.001d 1.49 (1.16–1.92)a 0.002d
Microbleeds, presencee 6.52 (2.21–19.22) 0.001d 5.68 (1.92–16.84)a 0.002d
Microbleeds, per numbere 1.08 (0.99–1.18) 0.083 1.10 (1.01–1.21)a 0.035
White matter volume, per SD (mL) 0.64 (0.33–1.23) 0.177 0.51 (0.24–1.07)a 0.073
Gray matter volume, per SD (mL) 0.32 (0.16–0.64) 0.001d 0.39 (0.19–0.77)b 0.007d
Hazard ratio (95% CI),
adjusted for baseline age, sex,
baseline UPDRS-m score, and
territorial infarcts p Value
Hazard ratio (95% CI), in
addition adjusted for gray
matter volumea and SVD
characteristicsb p Value
Baseline DTI measures (n 5 492)f
White matter global FA, per SD 0.52 (0.30–0.89) 0.017 1.12 (0.59–2.11)a,b 0.729
WMH global FA, per SD 0.39 (0.19–0.77) 0.007d 0.87 (0.42–1.78)a,b 0.693
NAWM global FA, per SD 0.53 (0.31–0.91) 0.022 1.14 (0.60–2.17)a,b 0.681
White matter global MD, per SD 2.49 (1.40–4.43) 0.002d 0.83 (0.39–1.80)a,b 0.645
WMH global MD, per SD 3.77 (2.02–7.04) ,0.001d 1.81 (0.72–4.56)a,b 0.211
NAWM global MD, per SD 2.20 (1.19–4.06) 0.012 0.79 (0.38–1.62)a,b 0.514
Abbreviations: CI 5 confidence interval; DTI 5 diffusion tensor imaging; FA 5 fractional anisotropy; MD 5 mean diffusivity
(*1024 mm2/s); NAWM 5 normal-appearing white matter; per SD 5 hazard ratios per SD difference from the mean; SVD 5
small vessel disease; UPDRS-m 5 Unified Parkinson’s Disease Rating Scale motor score; WMH 5 white matter
hyperintensities.
a In addition adjusted for gray matter volume.
b In addition adjusted for SVD characteristics: including white matter volume, WMH volume, number of lacunes and
microbleeds.
c Five participants were excluded because of a diagnosis of parkinsonism other than vascular parkinsonism.
dSignificant after Bonferroni correction.
e Four participants were excluded because of missing values of microbleeds at baseline.
f Three participants were excluded in addition because of baseline DTI artefacts.
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thereafter, neuroimaging was used to allow for the
diagnosis of VP. Fourth, as imaging information is
needed to classify the different etiologies of parkinson-
ism, especially concerning VP, circular reasoning
might have occurred in our analyses with VP, although
we used baseline MRI and DTI measures, when all
participants were free of parkinsonism.
Even though this is a hospital-based cohort study,
our results have a high external validity for an elderly
population with SVD who visit a general neurology
department, as we included all consecutive patients
with SVD on neuroimaging (CT or MRI scan) per-
formed because of major referral reasons (e.g., TIA,
stroke, cognitive complaints) and there were no re-
strictions for admission to our hospital.
So far, the exact role of SVD in parkinsonism is
unknown. Some studies have suggested that WMHs
are more common in patients with parkinsonism,23,24
whereas others failed to demonstrate that.25,26 Fur-
thermore, in autopsy studies, only a small subset
(,10%) of parkinsonism was attributed to vascular
lesions, because of the absence of other pathologic
findings (Lewy bodies or tau inclusions) compatible
with a known parkinsonian syndrome.22
Our findings favor a role for SVD in the develop-
ment of parkinsonism, as we showed that participants
with a high degree of SVD had an increased risk of
incident parkinsonism. Furthermore, we found a rel-
atively high incidence of parkinsonism compared to
population-based studies; in the Rotterdam Study,
2% of the 6,566 participants ($55 years) developed
(any) parkinsonism after a mean follow-up duration
of 5.8 years,19 vs 4% in our study, which may also
indicate that SVD contributes to the etiology of
parkinsonism.
DTI has gained increased interest in the diagnostic
process of parkinsonism in recent years,8 as it has been
suggested that this technique could be of help in dif-
ferentiating among the different subtypes of parkin-
sonism.27,28 We therefore performed a TBSS analysis
in patients with a clinical diagnosis of VP, because
this was the largest group of patients in our study and
a recent study showed that DTI can differentiate
between VP and parkinsonian syndromes of degener-
ative origin.28 We found lower FA values in bilateral
WM tracts involved in movement control in VP com-
pared to participants without parkinsonism, even
after adjustment for SVD characteristics. This result
is in line with a recent cross-sectional DTI study in
patients with VP and healthy controls; however, no
adjustments were made for SVD.9 Using DTI meas-
ures of scans at a point in time when all participants
Figure 2 Differences in fractional anisotropy values between participants with vascular parkinsonism and
without parkinsonism
Voxel-wise analysis of the differences in fractional anisotropy (FA) values between participants with vascular parkinsonism
(n 5 9) and without parkinsonism (n 5 427). Adjusted for age, sex, baseline motor part of the Unified Parkinson’s Disease
Rating Scale score, and normalized total brain volume (A) and for small vessel disease characteristics (white matter volume,
white matter hyperintensity volume, and number of lacunes and microbleeds) (B), performed with a 2-sample t test, thresh-
olded at p , 0.025 and corrected for multiple comparisons. These images are superimposed onto the spatially normalized
Montreal Neurological Institute (MNI) stereotactic space FA map. The x, y, and z coordinates represent the MNI coordinates
of each slide.
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were free of parkinsonism is unique in our study. Our
results may suggest that diffusion changes can be an
early marker of VP. However, a note of caution is due
here owing to the small number of patients with VP
in our study.
We can hypothesize about the role of SVD in par-
kinsonism; it may be that SVD disrupts the structural
integrity of WM tracts, including disruption of the
thalamocortical fibers, thereby reducing the influence
of the basal ganglia on motor, premotor, and supple-
mentary motor cortices.29 Disconnection of the basal
ganglia–thalamocortical circuit possibly leads to (sub)
cortical atrophy, ultimately resulting in parkinsonism.
Furthermore, SVD could possibly lower the threshold
for developing parkinsonism, by lowering the thresh-
old for Lewy body pathology to become sympto-
matic, for example. In addition, marked loss of
striatal dopaminergic innervations that occurs during
aging might contribute as well.30
Future studies are needed to further investigate the
contribution of SVD to incident parkinsonism, ide-
ally taking into account the changes in these imaging
markers over time.
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